# US 2020/0393445 A1 · Methods to identify modulators of actin-binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0393445 A1
- Document ID: US20200393445A1
- Status: Published application
- Kind: A1
- Application number: 16/897,977
- Filed: 2020-06-10
- Published: 2020-12-17
- Earliest claimed: 2019-06-11
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Adam William Avery; Thomas S. Hays; David D. Thomas; Michael E. Fealey; Robyn T. Rebbeck
- Web page: https://patentgrep.com/patent/US20200393445A1

## CPC

- G01N 21/6408: {with measurement of decay time, time resolved fluorescence}
- G01N 33/502: {for testing non-proliferative effects}
- G01N 21/6428: {Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes" (in vivo A61B5/00; immunoassay G01N33/53)}
- G01N 33/542: with steric inhibition or signal modification, e.g. fluorescent quenching
- G01N 2021/6439: {with indicators, stains, dyes, tags, labels, marks}
- G01N 2021/6441: {with two or more labels}
- G01N 2333/4712: Muscle proteins, e.g. myosin, actin, protein
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure provides methods for identifying compounds that cause structural changes in a protein bound to an actin filament. The methods include the use of cells that include two actin-binding proteins, each labeled with a chromophore, and exposing the cells to a test compound. The method further includes detecting a change in fluorescence resonance energy transfer (FRET) between the chromophores.

## Claims

### Claim 1

A method for identifying a compound that alters fluorescence resonance energy transfer (FRET) of a protein comprising:
providing a genetically engineered cell comprising a first protein and a second protein,
wherein the first protein comprises a first heterologous domain that comprises a first probe, and the first protein comprises either a CH domain-containing actin-binding domain or a tandem-CH, actin-binding domain,
wherein the second protein comprises a second heterologous domain that comprises a second probe;
wherein each protein binds to an actin filament in the cell in a spatial proximity to result in detectable FRET between the first and second probes;
contacting the cell with a test compound to form a mixture; and
measuring the fluorescence lifetime of the first probe, the second probe, or the combination thereof

### Claim 2 (depends on 1)

The method of claim 1, wherein a difference between the fluorescence lifetime in the presence of the test compound and the fluorescence lifetime in the absence of the test compound indicates that the test compound alters the FRET of the target protein.

### Claim 3 (depends on 1)

The method of claim 1 wherein the second protein is a fusion protein comprising a Lifeact protein and a red fluorescent protein.

### Claim 4 (depends on 1)

The method of claim 1 wherein the Förster distance between the first probe and the second probe is at least 52 angstroms (Å).

### Claim 5 (depends on 1)

The method of claim 1 wherein the first heterologous domain is located at the amino-terminal end of the first protein.

### Claim 6 (depends on 1)

The method of claim 1 wherein the first heterologous domain is located at the carboxy-terminal end of the first protein.

### Claim 7 (depends on 1)

The method of claim 1 wherein the first probe is a donor probe and the second probe is an acceptor probe.

### Claim 8 (depends on 1)

The method of claim 1 wherein the measuring comprises capturing fluorescence lifetime waveforms emitted by the donor probe or the acceptor probe.

### Claim 9 (depends on 1)

The method of claim 1 wherein the fluorescence lifetime of the donor probe is changed in the presence of the test compound.

### Claim 10 (depends on 9)

The method of claim 9 wherein the fluorescence lifetime of the donor probe is reduced in the presence of the test compound.

### Claim 11 (depends on 1)

The method of claim 1 wherein the fluorescence lifetime of the donor probe is unchanged in the presence of the test compound.

### Claim 12 (depends on 1)

The method of claim 1 wherein the cell is exposed to the excitation light for no greater than 5 seconds.

### Claim 13 (depends on 1)

The method of claim 1 wherein the first protein comprises a wild-type protein that further comprises the first heterologous domain.

### Claim 14 (depends on 1)

The method of claim 1 wherein the first protein is a mutant actin-binding proteins comprising a wild-type protein and at least one mutation.

### Claim 15 (depends on 1)

The method of claim 1 wherein the at least one mutation is present in the tandem-CH, actin-binding domain or in the CH domain-containing actin-binding domain.

### Claim 16 (depends on 14)

The method of claim 14 wherein the mutant actin-binding protein binds the actin filament with an affinity that is greater than the first protein in the absence of the at least one mutation.

### Claim 17 (depends on 1)

The method of claim 1 wherein the first protein comprises β-III-spectrin, the β-III-spectrin comprising a mutation that correlates with disease in a human.

### Claim 18 (depends on 20)

The method of claim 20 wherein the disease is spinocerebellar ataxia type 5.

### Claim 19 (depends on 20)

The method of claim 20 wherein the mutation is L253P.

### Claim 20 (depends on 1)

The method of claim 1 further comprising performing a counter screen, wherein the counter screen comprises:
providing a genetically engineered cell comprising the first protein and the second probe;
contacting the cell with the test compound to form a mixture; and
measuring the fluorescence lifetime of the first probe, the second probe, or the combination thereof.
